Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Active not recruiting 1

Sponsor Class

INDUSTRY 13OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 21Gastrointestinal 16Other solid neoplasm 5Head & Neck 5Breast 4Thoracic 3Sarcoma 3Genitourinary 2Endocrine 2Dermatologic 2Tumor-Agnostic 1CNS 1

Conditions

Lung Neoplasms 2Small Cell Lung Carcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × dostarlimab × Thoracic × Clear all
NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
48 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04940637 2023-05-12

UNITO-001

University of Turin, Italy

Phase 2 Unknown
70 enrolled
Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT03654833 2023-03-14

MiST

University of Leicester

Phase 2 Unknown
186 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡